Reduces Cost
Process enhancement and indigenous technology development lower unit economics at the molecular level — continuously, without third-party constraints.
Research & Development
R&D is Not a Function. It is How we Grow.
At Balaji Amines, Research and Development is the mechanism by which import gaps are converted into products, complexity is translated into commercial capability, and India's chemical dependence is systematically reduced.
Every molecule in the current pipeline — electronic-grade DMC, DME, NMM, NBPT — began as an in-house R&D programme. No external licences. No acquired technology. The pipeline is self-generating.
What R&D Does at Balaji Amines
Elevates Quality
Proprietary process control enables the purity and consistency levels required by regulated pharma, EV, and export markets.
Expands the Value Chain
Moves the portfolio beyond commodity amines into high-margin derivatives and speciality chemicals - each one an import India no longer needs.
Builds Relevance
Molecules designed for where demand is going: pharma intermediates, EV battery chemistry, agrochemical actives, speciality solvents.
What R&D Has Already Delivered
The pipeline table below shows what is commissioned, what is in execution, and what is next in line. Three proof points explain why it matters.
Only Indian manufacturer:
R&D contributions have made Balaji Amines the only Indian manufacturer with certain indigenous technologies for core products. This position reinforces supply security and quality control in ways competitors cannot immediately bridge.
Concept to commercial scale:
Electronic-grade DMC and pharma-grade Propylene Glycol have both moved from internal process development to commissioned production — and are now accepted by customers in regulated markets. The R&D-to-plant pathway is proven.
A broad base, not a single bet:
Proprietary processes cover amines, derivatives, performance solvents, and intermediates. The R&D capability that produced electronic-grade DMC is the same capability that is producing the next wave: NMM, NBPT, and ACN, with an improved process.
R&D Pipeline
Every product below was enabled by in-house process development. The pipeline is not a wish list — it is a sequence of R&D programmes at different stages of commercial realisation.
| Product / Project | Scale | Status |
|---|---|---|
| Commissioned | ||
| Electronic-Grade DMC | 15,000 TPA | Commissioned. Accepted by customers in EV battery supply chain. |
| In Execution — FY27 | ||
| Dimethyl Ether (DME) | 1,00,000 TPA | Commissioned Q1 FY27. India's first commercial-scale plant. |
| N-Methyl Morpholine (NMM) | ~5,000 TPA | Civil works complete. Commissioning FY27. |
| Acetonitrile (ACN) expansion | 60 MT/day | Improved process. Greenfield at Unit III. FY27 target. |
| Iso Propyl Amines (MIPA/DIPA) | 20-21 MT/day | Reconfigured from existing Ethyl Amines facility. Operational. |
| BSCL - EDA derivatives (Unit I) | DETA, TETA, PIP, AEEA, AEP | Brownfield. Commissioning H1 FY27. |
| BSCL — HCN, NaCN, EDTA (Unit II) | ₹750 crore project | Greenfield, Chincholi. Commissioning Q4 FY27. |
| Next Phase | ||
| NBPT | 2,500 TPA | Proposed. Immediately after FY26. Agrochemical / urease inhibitor. |